REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results for the year ended 31 March 2011

14 Nov 2011 07:01

14 November 2011 Sterling Green Group plc ("Sterling Green" or "the Company") Final Results for the year ended 31 March 2011

CHAIRMAN'S STATEMENT

Introduction and review of activities

I am pleased to present the financial statements of Sterling Green Group plc and its subsidiaries ("the Group") covering the year ended 31 March 2011. As forecast in my Chairman's Statement accompanying the interim results announcement in November 2010, I am able to report the Group's maiden profit for the full year ended 31 March 2011.

Results and dividends

Revenue for the year ended 31 March 2011 was £2,801,000 (2010 - £2,106,000). Revenue was made up of £2,681,000 (2010 - £1,977,000) from debt management services and £120,000 (2010 - £129,000) relating to mortgage business.

The Group profit after taxation for the year amounted to £32,000 (2010 - £ 238,000 loss). The Directors are not able to recommend the payment of a dividend.

Trading review

The Group's overall performance during the year showed a significant improvement on the prior year's results as the Group was able to increase total revenues by 33%, while maintaining its gross margins and restricting the increase in total overhead costs to just 2.8%.

Debt management revenues of £2,681,000 for the year reflected an increase of 35.6% on the prior year figure of £1,977,000. Gross margins on debt management were only slightly down at 46.4% compared to 47.6% whilst debt management overheads of £983,000 were £51,000 or 5.5% higher than the £932,000 shown in the prior year. Overall, debt management activities showed an operating profit of £262,000 compared with an operating profit of £10,000 in the prior year.

Re-mortgaging revenues of £120,000 were down on the prior year figure of £ 129,000. However, further cost cutting during the year enabled this activity to show an operating profit of £33,000 compared to £12,000 in the prior year.

Current performance and future developments

Disappointingly, the Group's debt management activities have shown a small loss in the period since the year end.

Whilst the Group has been successful in growing its client base and the associated revenues derived from those clients, it has struggled in a very competitive environment, to generate sufficient income and profits to fully offset the costs associated with the Company being on AIM. The Company has seen a marked increase in costs associated with acquiring robust client leads and, in order to grow the business, the Group has taken on debt to fund specific marketing campaigns and/or payments to lead providers. As a result, the on-going running costs are now at a level that would require substantial growth in the Group's client base in order to continue to be able to service the debt and maintain the Group's lead generation programme. The Directors believe that the Group does not have the necessary capital or ability to raise sufficient capital to compete with other larger competitors.

As a result, the Company has entered into a conditional sale and purchase agreement to dispose of the majority of its debt management book (the "Debt Books"). DRSP Limited has agreed to acquire the Debt Books for a price of £ 50,000 plus an amount equal to 12 times the total average monthly fee of the Debt Books. The Directors estimate that this will be approximately £1.05 million on completion, with the consideration being satisfied entirely in cash.

STERLING GREEN GROUP PLC CHAIRMAN'S STATEMENT (continued)

___________________________________________________________________________

The transaction is dependent upon shareholder approval and a Circular has today been sent to shareholders outlining the details of the proposed transaction. In the opinion of the Directors, the proposed disposal represents the best chance for shareholders to realise some value from their investment.

The proposed disposal constitutes a fundamental change of business under Rule 15 of the AIM Rules and is, therefore, conditional on shareholder approval. If the transaction is approved by shareholders, the Group will have limited trading activities, which in the absence of a sale, the Directors anticipate will continue for the foreseeable future. The proceeds of the disposal will be used to repay the Group's indebtedness amounting to approximately £440,000 and for working capital generally. Following the disposal the Group will retain cash balances of approximately £500,000 after repaying debt, certain other long term creditors and expenses relating to the transaction.

J M EdelsonChairman14 November 2011Further enquiries:Sterling Green Group plc Tel: 0161 975 5757 Michael Edelson Merchant Securities Limited Tel: 020 7628 2200 Simon Clements/David Worlidge

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 MARCH 2011

Note 2011 2010 £000 £000 Revenue 2,801 2,106 Cost of sales (1,506) (1,128) Gross profit 1,295 978 Administrative expenses (1,175) (1,143) Profit/(Loss) from operations 120 (165) Finance costs (88) (72) Profit/(Loss) before tax 32 (237) Income tax charge 2 - (1) Profit/(Loss) and total comprehensive 32 (238) income for the year attributable to equity holders of the parent Earnings/(Loss) per share 3 0.01p (0.08p) Basic and diluted

There were no other items of comprehensive income other than the profit for the year.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2011

Note 2011 2010 £000 £000 Non-current assets Intangible assets 1,115 1,115 Property, plant and equipment 89 116 Total non-current assets 1,204 1,231 Current assets Trade and other receivables 143 108 Cash and cash equivalents 44 28 Total current assets 187 136 Current liabilities Trade and other payables (243) (361) Current tax liabilities - (1) Borrowings (424) (39) Total current liabilities (667) (401) Net current liabilities (480) (265) Non-current liabilities Borrowings (5) (279) Total non-current liabilities (5) (279) Net assets 719 687 Equity attributable to the owners of the parent Called up share capital 304 304 Share premium account 1,794 1,794 Capital reserve 6 6 Other reserve 891 891 Accumulated losses (2,276) (2,308) Total equity 719 687

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2011

Note 2011 2010 £000 £000 Cash flows from operating activities Profit/(Loss) before tax 32 (237) Adjustments for: Depreciation of property, plant and equipment 62 98 Finance costs 88 72 Operating cash flows before movement in working 182 (67)capital (Increase)/Decrease in trade and other (35) 34receivables (Decrease)/Increase in trade and other payables (118) 42 Corporation tax paid (1) - Net cash from operating activities 28 9 Cash flows used in investing activities Purchase of property, plant and equipment (35) (5) Net cash used in investing activities (35) (5) Cash flows from/(used in) financing activities Capital element of lease payments (39) (86) Loans received 150 - Finance costs paid (88) (72) Net cash from/(used in) financing activities 23 (158) Net increase/(decrease) in cash and cash 16 (154)equivalents Cash and cash equivalents at the start of the 28 182year Cash and cash equivalents at the end of the 4 44 28year

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2011

Attributable to equity holders of the parent Share Share Share Capital Other Accum-ulated Total capital premium capital reserve reserve losses £000 £000 account to be £000 £000 £000 £000 issued £000

At 1 April 2009 288 1,710 100 6 891 (2,070) 925

Loss and total - - - - - (238) (238)comprehensive income for the year Issue of share 16 84 (100) - - - -capital

At 31 March 2010 304 1,794 - 6 891 (2,308) 687

Profit and total - - - - - 32 32comprehensive income for the year

At 31 March 2011 304 1,794 - 6 891 (2,276) 719

Other reserve

The other reserve is a merger reserve created on the acquisition of Sterling Green Limited.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2011

1. Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.

The financial information set out above does not comprise the Company's statutory accounts for the periods ended 31 March 2011 or 31 March 2010. Statutory accounts for 31 March 2010 have been delivered to the Registrar of Companies and those for 31 March 2011 will be delivered in due course. The auditors have reported on those accounts. The accounts did not contain a statement under the Companies Act 2006 s498(2) or (3), and both received an unqualified audit opinion. However there was an emphasis of matter in relation to going concern.

The Board has considered the Group's financial position and trading prospects using detailed forecasts covering the period ending 31 March 2013, which incorporate the current drawn down loan facility confirmed as available until 18 December 2011. These forecasts have been drawn up on the basis that the existing loan will be repaid following completion of the proposed partial Disposal of the Group's debt management book. On the basis that the partial Disposal is completed and having made appropriate consideration, the Board believes that the Group has adequate resources to continue trading for the foreseeable future, and accordingly, the going concern basis has been adopted in preparing these financial statements.

Additionally as the partial Disposal is subject to shareholder approval, the Board has considered the Group's financial position and trading prospects using detailed forecasts covering the period ending 31 March 2013 on the basis that the proposed partial Disposal of the Group's debt management book does not complete. These forecasts have been drawn up on the basis that the existing loan will not be repaid and accordingly the Group would have to apply for a further extension of that loan facility. Although the Board is not aware of any reason why a further extension would not be granted, there is no certainty that the Group would be able to extend those facilities beyond 18 December 2011. This represents a material uncertainty related to events or conditions which may cast significant doubt on the Group's and the Company's ability to continue as going concerns and, therefore, that they may be unable to realize their assets and discharge their liabilities in the normal course of business. However, subject to this uncertainty, the Board believes that the Group has adequate resources to continue trading for the foreseeable future, and accordingly, the going concern basis has been adopted in preparing these financial statements.

2. Income tax charge 2011 2010 £000 £000 Current year tax: UK corporation tax - - Prior year tax: UK corporation tax underprovided - (1) - (1)

Corporation tax is calculated at 28% (2010 - 28%) of the estimated assessable profit for the year.

The tax charge for the year can be reconciled to the consolidated statement of comprehensive income as follows:

2011 2010 £000 £000 Profit/(Loss) before tax 32 (237) Loss on ordinary activities multiplied by 9 (66) the relevant standard rate of corporation tax in the UK of 28% (2010 - 28%) Effect of: Income not taxable/expenses not deductible (5) 8 for tax purposes Utilisation of losses (4) - Losses carried forward - 58 UK corporation tax underprovided in prior - (1) year Current tax charge for the year - (1)

Unrecognised deferred tax assets

The following deferred tax assets have not been brought into account as assets:

2011 2010 £000 £000 Tax losses 532 534 Temporary differences 52 60 3. Earnings/(Loss) per share

The calculation of basic earnings/(loss) per share is based on the following:

2011 2010 Earnings/(Loss) 32 (238) Earnings/(Loss) for the purpose of basic and diluted earnings /(loss) per share being the net profit/(loss) attributable to equity holders of the parent (£000) Number of shares 303,675,390 303,587,719 Weighted average number of shares for the purpose of basic earnings/(loss) per share Effect of dilutive potential ordinary 12,567,280 -shares: - Share options

Weighted average number of ordinary shares 316,242,670 303,587,719

for the purpose of diluted earnings/(loss) per share Earnings/(Loss) per share (pence) 0.01 (0.08) Basic Diluted 0.01 (0.08)

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue assuming conversion of all dilutive potential ordinary shares. During the year the Company's potential ordinary shares consist of share options. Due to losses in the preceding year there are no dilutive ordinary shares in that year.

4. Notes to the cashflow statement

Cash and cash equivalents

Cash and cash equivalents consist of bank balances. Cash and cash equivalentsincluded in the cash flow statement comprise the following balance sheetamounts: 2011 2010 £000 £000 Cash at bank 44 285. Related party transactions

The services of J M Edelson were provided to the Group under a service agreement by London & City Credit Corporation Limited. Amounts charged to the Group during the year for his services amounted to £25,000 (2010 - £25,000). At 31 March 2011 £2,500 (2010 - £2,448) of this amount remained outstanding.

S. T. Ali and J. McClean have provided personal guarantees up to a maximum of £ 250,000 as security for the £400,000 loan facility available to the Group.

6. Dividend

The directors are not able to recommend the payment of a dividend.

7. Copies of the Report & Accounts

Copies of the Report & Accounts will be posted to shareholders shortly and are also available from the Company's registered office at Number 14, The Embankment, Vale Road, Heaton Mersey, Stockport, Cheshire SK4 3GN and from the Company's website www.sterlinggreen.co.uk.

38

XLON
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.